HIV-1 Integrase Polymorphisms and Antiretroviral Drug Exposure
Author Information
Author(s): Sebastiaan J van Hal, Belinda Herring, Zaquan Deris, Bin Wang, Nitin K Saksena, Dominic E Dwyer
Primary Institution: Centre for Infectious Diseases and Microbiology, ICPMR Westmead Hospital, University of Sydney
Hypothesis
Are HIV-1 integrase polymorphisms associated with prior antiretroviral drug exposure?
Conclusion
Ongoing surveillance of integrase inhibitor polymorphisms is crucial, and integrase sequencing should be performed before starting integrase inhibitors.
Supporting Evidence
- Primary integrase inhibitor mutations were rare in integrase inhibitor-naïve individuals.
- Previous antiretroviral therapy was linked to greater integrase gene divergence.
- G140S mutation was detected in two INI-naïve patients, suggesting a link to prior therapy.
Takeaway
Researchers found that some changes in HIV-1 can happen because of past treatments, and it's important to check these changes before giving new medicines.
Methodology
Plasma from 133 INI-naïve patients was sequenced across the integrase gene.
Limitations
The study had a small sample size for some subtypes, limiting the ability to draw firm conclusions.
Participant Demographics
Most participants were HIV-1 subtype B (n = 109), with others from subtypes A, C, G, and CRFs.
Statistical Information
P-Value
p < 0.01
Confidence Interval
5.1% +/- 0.17 for treatment-experienced patients; 3.8% +/- 0.18 for treatment-naïve patients
Statistical Significance
p < 0.01
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website